{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 25,
        "end": 33
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 78,
        "end": 81
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 86,
        "end": 96
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 136,
        "end": 140
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 143,
        "end": 152
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 155,
        "end": 165
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 172,
        "end": 180
      }
    },
    {
      "id": "T12",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 125,
        "end": 133
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "25940539_9",
  "text": "The anticancer effect of CUDC-101 was associated with increased expression of p21 and E-cadherin , and reduced expression of survivin , XIAP , b-catenin , N-cadherin , and Vimentin ."
}
